Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

October 5, 2021 07:20 AM EDTUpdated 03:47 PM

Covid-19 roundup: Scientists pull pre-print with inflated incidence of myocarditis post mRNA vaccine; AstraZeneca seeks EUA for long-acting antibody

Zachary Brennan

Senior Editor

Canadian scientists recently withdrew an alarming pre-print manuscript that mistakenly said the incidence of the heart condition myocarditis was a lot more frequent than actually …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Scientists pull pre-print with inflated incidence of myocarditis post mRNA vaccine; AstraZeneca seeks EUA for long-acting antibody

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Covid-19 roundup: Sci­en­tists pull pre-print with in­flat­ed in­ci­dence of my­ocardi­tis post mR­NA vac­cine; As­traZeneca seeks EUA for long-act­ing an­ti­body

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Covid-19 roundup: Scientists pull pre-print with inflated incidence of myocarditis post mRNA vaccine; AstraZeneca seeks EUA for long-acting antibody